This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Methods We systematically searched PubMed/MEDLINE, EMBASE and Cochrane CENTRAL from inception to 22 January 2024. Beta-blockers probably prevent atrialfibrillation with a large magnitude of effect (RR 0.4, to 0.59) may reduce the risk of postoperative atrialfibrillation. 95% CI 0.20
ObjectiveThis study aimed to investigate the effects of Enhanced External Counterpulsation (EECP) on anxiety and depression in patients with Paroxysmal AtrialFibrillation (PAF).MethodsA MethodsA cohort of 100 patients diagnosed with PAF at the Fuzhou First Hospital between January 2023 and June 2024 were enrolled in this study.
Nature Reviews Cardiology, Published online: 28 February 2024; doi:10.1038/s41569-024-01004-2 Atrialfibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers.
Radiofrequency ablation (RFA) is an important therapeutic modality for atrialfibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. A 71-year-old male admitted to the emergency department on July 19, 2024, with acute loss of consciousness and convulsions.
Previous studies evaluated its value in predicting atrialfibrillation (AF) occurrence. However, its predictive efficacy for AF recurrence remains controversial.MethodsWe searched PubMed and Google databases for studies before January 2024 evaluating the association between QTc interval and AF incidence.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrialfibrillation ablation, Musat et al. recommend shortening the blanking period from three months to one. also emphasize the importance of continuous monitoring.
Nature Reviews Cardiology, Published online: 25 September 2024; doi:10.1038/s41569-024-01091-1 The burden of atrialfibrillation (AF) is increasing worldwide; however, most existing data on AF epidemiology are from Western regions.
Nature Reviews Cardiology, Published online: 30 May 2024; doi:10.1038/s41569-024-01038-6 In this Review, the authors describe the changes in metabolism that predispose individuals to developing atrialfibrillation (AF) and highlight the potential of available and emerging therapeutic strategies that target metabolic remodelling to treat AF.
ABSTRACT This state-of-the-art review is based on the Philippe Coumel Lecture in 2024 (Figure 1). It highlights the confluence of two major cardiovascular epidemics, atrialfibrillation and heart failure, with preserved ejection fraction.
There is a dose-response relationship between rising outdoor temperatures and increased atrialfibrillation (AF) events, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.
Food and Drug Administration approval of the FARAPULSE PFA System in the first quarter of 2024. The company now anticipates U.S. Additional information about clinical evidence supporting the device can be found here. Caution: Investigational Device. Limited by Federal (or US) law to investigational use only. Circulation.
tim.hodson Mon, 11/18/2024 - 10:55 Nov. Given the elevated bleeding risks associated with traditional anticoagulants, particularly when combined with antiplatelet agents, abelacimab may offer a safer alternative for patients with atrialfibrillation,” said Christian T.
milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio.
Data regarding AF screening in conflict countries emergency departments (ED) is lacking.MethodsWe included consecutive patients >40 years old who reported to the ED of a Syrian tertiary centre between July 2024 and September 2024. Patients had routine 12-lead electrocardiograms (ECGs) regardless of presenting complaints.
We conducted a comprehensive bibliometric analysis of PFA use in AF treatment to map research trends, collaborations, and future directions.MethodsWe extracted data from the Web of Science Core Collection on September 6, 2024, using search terms related to PFA and AF.
milla1cf Wed, 05/15/2024 - 19:05 May 15, 2024 — CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced its participation at the Heart Rhythm 2024 conference, taking place in person at the Boston Convention & Exhibition Center and virtually, May 16-19, 2024.
The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology. On Thursday, Sept. On Thursday, Sept.
Three important studies were presented at HRS 2024 to make the case for PFA: Boston Scientific’s Faradise study (Farapulse PFA) showed similar efficacy to thermal ablation, but significantly shorter procedure time, which theoretically translates to better operational efficiency and better patent safety (less time with fluoroscopy).
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrialfibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. 2024, May 15).
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023.
In patients with device-detected atrialfibrillation and a prior stroke, oral anticoagulation increases bleeding without a clear reduction in stroke. This finding was presented by Prof. May 16–19.
milla1cf Thu, 03/07/2024 - 20:10 March 7, 2024 — GE HealthCare will showcase its industry-leading portfolio of artificial intelligence ( AI )-enabled medical devices and digital solutions in Booth 2500 at the Health Information and Management Systems Society ( HIMSS ) Global Health Conference and Exhibition in Orlando, FL from March 11-15, 2024.
We appreciate the immense effort undertaken by the writing committee to produce the outstanding 2024 Consensus Statement on Catheter and Surgical Ablation of AtrialFibrillation (AF)(1). A notable omission exists in section 7.4:
milla1cf Fri, 02/02/2024 - 17:02 February 2, 2024 — Biosense Webster, Inc. , Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. In: AF Symposium.; February 2-4; Boston.
Bailey, MD FACC, discuss the Top Electrophysiology (EP) Takeaways from 2024. Dr. Lakkireddy discusses climate change, high school mandated education on cardiopulmonary resuscitation, important trials impacting atrialfibrillation including PROMPT-AF and ARREST-AF, and more.
Atrialfibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
Getty Images milla1cf Tue, 02/27/2024 - 17:24 February 27, 2024 — Biosense Webster, Inc. , Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment.
tim.hodson Tue, 11/19/2024 - 15:57 Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to treat people with atrialfibrillation (AFib) who are at an increased risk of stroke. 16-18, 2024).
Heart Rhtyhm recently published two large cohort studies, Chen et al, 2024, “Low remnant cholesterol and the subsequent risk of new-onset atrialfibrillation: A prospective cohort study” (1) and Ouyang, et al 2024, “Remnant Cholesterol and New-onset AtrialFibrillation: The Atherosclerosis Risk in Communities Study” (2).
A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrialfibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented Sept.
Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for AtrialFibrillation Treatment 8. Weight Loss Drug Linked with Reduced Need for Diuretics in Heart Failure Patients 7. Tenax Therapeutics Announces New U.S.
ISC 2024 Late-breaking Science Finding from ZODIAC Study: Position of Head Before Surgery May Improve Stroke Patient’s Neurological Function 3. ISC 2024 News: Late-Breaking Science Findings from EMBOLISE Clinical Trial Reveals Blocking Artery Supplying the Brain Covering After Subdural Hematoma Reduced Repeat Surgery 4.
Introduction:Continuous electrocardiographic monitoring using an implantable loop recorder (ILR) can facilitate the detection of asymptomatic atrialfibrillation episodes. The median time from implantation to the first detected atrialfibrillation was 115.7 The total positive detection of atrialfibrillation was 12 cases.
Mass screening for atrialfibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug–2 Sept).
Methods We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, the WHO International Clinical Trials Registry Platform and bibliographies of included trials, guidelines and other reviews from inception to 17 September 2024.
milla1cf Mon, 01/08/2024 - 14:35 January 8, 2024 — University Hospitals (UH) Harrington Heart & Vascular Institute recently became the first center in the world to implant Medtronic’s Penditure Left Atrial Appendage (LAA) Exclusion System through a minimally invasive approach during a mitral valve repair procedure.
Digoxin has been used in the management of chronic heart failure (HF) and atrialfibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.
intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. Image courtesy: Boston Scientific christine.book Wed, 01/31/2024 - 11:13 January 31, 2024 — Boston Scientific Corporation announced it has received U.S.
This study of 16 patients with persistent left superior vena cava (PLSVC) undergoing atrialfibrillation ablation shows a 66.7% Abstract Objectives To investigate tailored approaches, techniques, and outcomes of catheter ablation in patients with persistent left superior vena cava (PLSVC) undergoing atrialfibrillation (AF) ablation.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content